We analyzed LAG-3 transcriptomic expression among 514 patients with diverse cancers, including 489 patients with clinical annotation for their advanced malignancies. LAG-3 is highly variable both across and within tumor types, and weakly correlated with other checkpoints like PD-L1, PD-1, and CTLA-4.

The use of immune checkpoint inhibitors (ICI) in patients with bladder cancer (BC) is currently limited. Patients with BC who have experienced loss of the Y chromosome (LOY) often exhibit an aggressive cancer phenotype. In these LOY BC cases, CD8+ T cell exhaustion hampers the development of a robust anti-tumor response.

T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) is an immune checkpoint inhibitor that suppresses immune function. Our study investigated TIM-3 transcriptomic expression in 514 cancers and found high expression in 90 (17.5%) tumors. Pancreatic cancer showed the highest expression of TIM-3.

Comprehensive genomic profiling (CGP) plays a key role in precision medicine as it enables simultaneous identification of multiple tumor biomarkers to guide cancer diagnosis, therapy selection, and prognostication. Thus, tissue stewardship for successful CGP is critical.

Manual scraping from formalin-fixed paraffin-embedded (FFPE) slides is inefficient and prone to error. The Xyall Tissector HT system automates tissue dissection, successfully scraping regions of interest (ROIs) with minimal deviation. It ensures consistent DNA/RNA quantity and quality, surpassing manual methods.

Library preparation for next-generation sequencing (NGS) is complex, laborious, and includes multiple repetitive steps, making these workflows suitable for automated solutions.